Keyphrases
Cost-effectiveness
100%
Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
100%
Nintedanib
100%
Placebo
28%
Quality-adjusted Life Years
28%
Incremental Cost-effectiveness Ratio
28%
Disease Progression
28%
Lung Transplantation
28%
Forced Vital Capacity
28%
Lung Function Decline
28%
Netherlands
14%
Simulation Model
14%
Patient Simulation
14%
Disease-related
14%
Quality of Life
14%
Sensitivity Analysis
14%
Usual Care
14%
Willingness-to-pay Threshold
14%
Economic Outcomes
14%
Clinical Outcomes
14%
Health Status
14%
Indirect Costs
14%
Parameter Influence
14%
Increased Mortality
14%
Health Gains
14%
Model Robustness
14%
10-year Follow-up
14%
Outcome Mortality
14%
Long-term Treatment
14%
Probability of Death
14%
Cost Variation
14%
Pulmonary Fibrosis
14%
Acute Exacerbation
14%
Direct Costs
14%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Interstitial Lung Disease
100%
Nintedanib
100%
Health Care Cost
57%
Placebo
28%
Quality Adjusted Life Year
28%
Disease Exacerbation
28%
Forced Vital Capacity
28%
Lung Transplantation
28%
Lung
28%
Quality of Life
14%
Disease
14%
Arm
14%
Health Status
14%
Pulmonary Fibrosis
14%
Down Syndrome
14%
Pharmacology, Toxicology and Pharmaceutical Science
Nintedanib
100%
Interstitial Lung Disease
100%
Placebo
28%
Disease Exacerbation
28%
Disease
14%
Health Status
14%
Lung Fibrosis
14%
Down Syndrome
14%